CD8A and neoplasm: In mice and in human cells cultured in vitro, CD8+ TIL can kill MHC-I–deficient tumor cells through the NKG2D–NKG2DL axis, enabling antigen-independent but priming-dependent cytotoxicity (Lerner et al, 2023).